Literature DB >> 21029327

Higher proportion of fast-twitch (type II) muscle fibres in idiopathic inflammatory myopathies - evident in chronic but not in untreated newly diagnosed patients.

I Loell1, S B Helmers, M Dastmalchi, H Alexanderson, L A Munters, I Nennesmo, E Lindroos, K Borg, I E Lundberg, M Esbjörnsson.   

Abstract

OBJECTIVE: Polymyositis and dermatomyositis are idiopathic, inflammatory myopathies characterized by proximal muscle fatigue. Conventional immunosuppressive treatment gives a variable response. Biopsies from chronic patients display a low proportion type I and a high proportion of type II muscle fibres. This raised a suspicion that the low proportion of type I fibres might play a role in the muscle fatigue. AIM: To investigate whether the muscle fibre attributes evident in chronic myositis are characteristic for the polymyositis and dermatomyosistis diseases themselves.
METHODS: Muscle biopsies were obtained from thigh muscle from untreated patients (n = 18), treated responders (n = 14) and non-responders (n = 6) and from healthy controls (n = 11), respectively. For clinical evaluations, creatine kinase, functional index of myositis and cumulative dose of cortisone were established.
RESULTS: Chronic patients had a lower proportion of type I fibres and a higher proportion of type II fibres compared to untreated myositis patients and healthy controls. Fibre cross-sectional area (CSA) did not differ between patients and healthy individuals but all women had a 20% smaller type II fibre CSA compared to men.
CONCLUSIONS: Untreated polymyositis and dermatomyositis patients and healthy controls have a different fibre type composition than chronic polymyositis and dermatomyositis patients. Fibre CSA did not differ between healthy controls or any of the patient groups. A low proportion of oxidative muscle fibres can therefore be excluded as a contributing factor causing muscle fatigue at disease onset and the gender difference should be taken into consideration when evaluating fibre CSA in myositis.
© 2010 The Authors. Clinical Physiology and Functional Imaging © 2010 Scandinavian Society of Clinical Physiology and Nuclear Medicine.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21029327     DOI: 10.1111/j.1475-097X.2010.00973.x

Source DB:  PubMed          Journal:  Clin Physiol Funct Imaging        ISSN: 1475-0961            Impact factor:   2.273


  8 in total

Review 1.  Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis.

Authors:  Angela B Robinson; Ann M Reed
Journal:  Nat Rev Rheumatol       Date:  2011-09-27       Impact factor: 20.543

Review 2.  Implications of glucocorticoid therapy in idiopathic inflammatory myopathies.

Authors:  Beatriz Y Hanaoka; Charlotte A Peterson; Craig Horbinski; Leslie J Crofford
Journal:  Nat Rev Rheumatol       Date:  2012-06-12       Impact factor: 20.543

3.  Improved skeletal muscle fatigue resistance in experimental autoimmune myositis mice following high-intensity interval training.

Authors:  Takashi Yamada; Yuki Ashida; Katsuyuki Tamai; Iori Kimura; Nao Yamauchi; Azuma Naito; Nao Tokuda; Håkan Westerblad; Daniel C Andersson; Koichi Himori
Journal:  Arthritis Res Ther       Date:  2022-06-27       Impact factor: 5.606

4.  Associations between muscle-related cytokines and selected patient outcomes in the ICU.

Authors:  Chris Winkelman; Kimberly D Johnson; Nahida Gordon
Journal:  Biol Res Nurs       Date:  2014-05-29       Impact factor: 2.522

5.  Aberrant repair and fibrosis development in skeletal muscle.

Authors:  Christopher J Mann; Eusebio Perdiguero; Antonio L Serrano; Yacine Kharraz; Susana Aguilar; Patrizia Pessina; Pura Muñoz-Cánoves
Journal:  Skelet Muscle       Date:  2011-05-04       Impact factor: 4.912

6.  Functional Index-3: A Valid and Reliable Functional Outcome Assessment Measure in Patients With Dermatomyositis and Polymyositis.

Authors:  Floranne C Ernste; Christopher Chong; Cynthia S Crowson; Tanaz A Kermani; Orla Ni Mhuircheartaigh; Helene Alexanderson
Journal:  J Rheumatol       Date:  2020-04-15       Impact factor: 4.666

7.  Improved exercise performance and increased aerobic capacity after endurance training of patients with stable polymyositis and dermatomyositis.

Authors:  Li Alemo Munters; Maryam Dastmalchi; Abram Katz; Mona Esbjörnsson; Ingela Loell; Balsam Hanna; Maria Lidén; Håkan Westerblad; Ingrid E Lundberg; Helene Alexanderson
Journal:  Arthritis Res Ther       Date:  2013-08-13       Impact factor: 5.156

8.  Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents.

Authors:  Ingela Loell; Joan Raouf; Yi-Wen Chen; Rongye Shi; Inger Nennesmo; Helene Alexanderson; Maryam Dastmalchi; Kanneboyina Nagaraju; Marina Korotkova; Ingrid E Lundberg
Journal:  Arthritis Res Ther       Date:  2016-06-10       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.